Abstract: The present study was aimed to formulate and develop raft forming chewable tablets of ranitidine hydrochloride for effective treatment of Gastro Esophageal Reflux Disease. Raft forming chewable tablet was developed using pectin as a raft forming polymer. Optimization of the formulation was done using 3 2 full factorial design. The tablets were evaluated for various physicochemical parameters and in vitro drug release study. Tablets have shown satisfactory results when evaluated for hardness, friability, weight variation, drug content, raft strength and acid neutralizing capacity. Out of all factorial batches i.e. F1 to F9, F6 has shown promising results of raft strength as it is sufficient for the prevention of the reflux in the esophagus.
Introduction
By novel drug delivery system, continuous delivery of the drug at a predictable kinetic over an extended period of time can be achieved. The advantage of this system includes reduction in the drug related side effects which is due to controlled therapeutic blood level instead of oscillating blood level. Another advantage is improved patient compliance because of reduced dosing frequency and reduction of total dose of the drug which is to be administered [1] .
Gastro retentive drug delivery system (GRDDS):
Gastro retentive drug delivery system is a site specific delivery system. It delivers the drug either in stomach or in intestine. The drug delivery is obtained by retention of dosage form in stomach and the drug is released in a controlled manner to the specific site either in stomach, duodenum or in intestine [2] .
Raft forming system [2],[3],[4],[5]
This system focus more for delivery of antacid and delivery of drugs used to treat gastrointestinal infection and disorders. The basic mechanism involves formation of viscous cohesive gel when the system comes in contact with gastric fluid. In this each portion of liquid swells and forms a continuous layer of gel known as raft. The raft floats because of buoyancy created by formation of CO 2 . This raft acts as a physical barrier to prevent the reflex of gastric content into the esophagus. This raft forming system contains a gel forming agent and alkaline bicarbonates or carbonates which is responsible for making the system less dense than the gastric fluid and to float on the gastric fluid. Sodium bicarbonate is used as a gas generating agent. Gas generating agent sodium bicarbonate interacts with the gastric acid and generates carbon dioxide which gets entrapped within the swellable matrix. Carbonate or bicarbonate may be present in the amount ranges from 5% to 50% and preferably from about 10% to 30% by weight of composition. Increasing the concentration of bicarbonate decreases the floating lag time because of faster and higher carbon dioxide generation. At higher concentration of effervescent agent, coating of the tablet becomes less stable. This is because of increase in the internal pressure and there by rupturing the polymer coating which ultimately results in sudden increase in drug release.
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Advantages of raft forming system:
 It is used for the treatment of heartburn and oesophagitis. It is also useful to treat laryngopharyngeal reflux (LPR) and gastro esophageal reflux disease.  It does not interfere with activity of anti secretory agent e.g. cimetidine.  Rapid and long duration of action can be achieved. It shows its action within seconds.  It may not interfere with the function of pyloric sphincter.  Improved patient compliance. 
Materials and Method

Materials
Ranitidine Hydrochloride, Pectin, Sodium Bicarbonate, Calcium Carbonate, Mannitol, PVP K30, Isopropyl Alcohol, Aspartame, Magnesium Stearate,Talc.
Method
Drug, polymer and other ingredients were weighed accurately. All ingredients except the binder and lubricant were mixed thoroughly. PVP K30 was dissolved in sufficient quantity of isopropyl alcohol and added to a powder mixture to prepare dough wet mass. The prepared wet mass was passed through a 22# sieve. The granules were allowed to dry in a hot air oven and then resifted through a 40# sieve. The granules were collected and lubricated. Tablets were compressed by a 12.7 mm diameter flat punch with the help of a rotary tablet compression machine. 
Evaluation Parameters
Pre-Compression Evaluation Parameters:
Angle of repose (θ), bulk density (gm/ml), tapped density (gm/ml), carr's index (%) and hausner's ratio were evaluated to determine the flow property of the prepared granule's mixture.
Post-Compression Evaluation Parameters
Weight Variation Test [6] :  Twenty tablets were randomly selected, weighed individually and the average weight was calculated. Not more than two of the individual weights deviate from the average weight by 5% as per IP 2010.  The Monsanto hardness tester was used to determine the tablet hardness. Scale was adjusted to zero and load was gradually increased until the tablet fractured. The value of the load at that point gave the measure of the hardness of tablet. Hardness was expressed in kg/cm 2 .
Drug Content [6]:
 Twenty tablets were weighted and powdered in a mortar. Accurately weighted quantity of the powder equivalent to about 168 mg of Ranitidine Hydrochloride was diluted to 100 ml with 0.1 N HCl in 100 ml volumetric flask. It was stirred for 15 minutes and filtered. 1 ml of the filtrate was diluted with 0.1 N HCl to produce 100mcg / ml solution. The absorbance of the resulting solution was measured at λmax 312.5 nm and the content of Ranitidine Hydrochloride was calculated from the absorbance obtained.
Raft Strength Measurement [7]:
 A tablet powder equivalent to unit dose was transferred to 150 ml of 0.1 N HCl and maintained at 37°C in a 250 ml glass beaker. Each raft was allowed to form around an L-shaped wire probe (diameter: 1.2 mm) held upright in the beaker throughout the whole period (30 min) of raft development. Raft strength was estimated using the modified balance method. Water was added drop wise to the pan and the weight of water required to break the raft was recorded.
Note: A double-pan dispensing balance was modified for raft strength measurement. One pan of the dispensing balance was replaced with an L-shaped wire probe as shown in Figure.  A tablet powder equivalent to unit dose was taken in a 250-ml beaker. Water was added to make a total volume of about 70 ml, heated to 37°C and stirred continuously by maintaining the temperature at 37°C. 30 ml of 1M hydrochloric acid (previously heated to 37°C) was added and mixture was maintained at 37°C for 15 minutes with continuous stirring. The excess acid was titrated with 1M sodium hydroxide to a pH of 3.5. The number of mEq of acid consumed by the tablet tested was calculated by the following formula:
Where, M HCl = molarity of hydrochloric acid M NaOH = molarity of sodium hydroxide V NaOH = volume of sodium hydroxide
In Vitro Drug Release Study [7] : Licensed Under Creative Commons Attribution CC BY 37 ± 0.5°C using a simulated gastric fluid (pH 1.2; 900 ml) as a dissolution medium. Unit dose was powdered and then added to the dissolution medium. At predetermined time intervals, 10-ml samples were withdrawn, filtered through a 0.45-μm membrane filter and analyzed at 312.5 nm using a UV spectrophotometer. Cumulative percentage drug release was calculated using an equation obtained from a calibration curve. The prepared granules for raft forming chewable tablets were characterized for angle of repose, bulk density, tapped density, carr's index and hausner's ratio which are shown in table. Angle of repose of all batches was within 31°-35°, carr's index of all batches was within 11 -20 and hausner's ratio of all batches was found within 1.12 -1.25 which indicate good flow property of granules. **Mean ± SD (n=6)  Hardness of tablets was found to be in the range of 4 -5 kg / cm 2 which is sufficient for chewable tablet. The friability of all tablets was found to be in range of 0.58% -0.79% which is less than 1% that showed good mechanical strength.  All batches had good raft strength which was within the range of 0.96-3.52 g and all batches had Acid Neutralizing Capacity within the range of 6.2 -7.2 mEq. Raft strength was found to be sufficient for prevention of reflux of gastric content into the esophagus. 100.05 ± 1.00 98.23 ± 0.9 100.12 ± 0.5 98.5 ± 0.8 99.98 ± 0.6 *mean ± SD (n=3)
Result and Discussion
Results of Preliminary Batches
 From the data, it was concluded that, formulation with maximum amount of pectin and calcium carbonate showed higher release of drug amonst all the batches. The prepared granules for raft forming chewable tablets were characterized for angle of repose, bulk density, tapped density, carr's index and hausner's ratio which are shown in table, which indicate good flow property of granules. **mean ±SD (n=6),* (n=2)  Hardness of tablets was found to be in the range of 4 -5 kg / cm 2 which is sufficient for chewable tablet. The friability of all tablets was found to be in range of 0.32% -0.98% which is less than 1% that showed good mechanical strength. 
Results of Factorial Batches
Conclusion
The raft forming chewable tablets of Ranitidine Hydrochloride were successfully formulated by wet granulation method. Pectin was used as a raft forming polymer and calcium carbonate was used to strengthen the raft formed by pectin. The formulation was optimized using two factors, three levels full factorial design. The amount of pectin (X 1 ) and amount of calcium carbonate (X 2 ) showed significant effect on the dependent variables Y 1 , Y 2 and Y 3 which was raft strength, Acid Neutralizing Capacity and % drug release respectively. In conclusion, the present study demonstrates the successful preparation of stable raft forming chewable tablets of Ranitidine Hydrochloride.
From all the result of factorial batches F1 to F9, F6 shows promising result for the raft strength which is sufficient for prevention of reflux in the esophagus.
